The U.S. Food and Drug Administration has granted priority review status to Bayer's supplemental new drug application for HYRNUO (sevabertinib) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE